Why the study?
Does nifedipine increase total mortality in patients with coronary disease?
Population
Patients with coronary disease from 16 randomized secondary-prevention trials
Comparison
Nifedipine vs Control groups from the included randomized trials
Design
Meta-analysis
Key result
In patients with coronary disease, short-acting nifedipine was associated with a dose-dependent increase in total mortality (overall RR 1.16; 95% CI 1.01-1.33; P=0.01 for dose response).
Authors
Loading...
Short-acting nifedipine should be avoided in coronary disease; challenges prior use and extends randomized evidence of dose-dependent mortality harm.
Meta-Analysis
Does nifedipine increase total mortality in patients with coronary disease?
The use of short-acting nifedipine in moderate to high doses causes a dose-dependent increase in total mortality in patients with coronary disease.
Effect estimate: RR 1.16 (95% CI 1.01 to 1.33)
p-value: p=.01
Furberg et al. (1995) conducted a meta-analysis in Coronary disease. Nifedipine was evaluated on Total mortality (RR 1.16, 95% CI 1.01 to 1.33, p=.01). In patients with coronary disease, short-acting nifedipine was associated with a dose-dependent increase in total mortality (overall RR 1.16; 95% CI 1.01-1.33; P=0.01 for dose response).